Literature DB >> 33368332

Quantitative detection of SARS-CoV-2 RNA in nasopharyngeal samples from infected patients with mild disease.

Patricia Bustos1, Carolina Tambley1, Alejandra Acevedo1, Winston Andrade1, Gabriel Leal1, Deyanira Vidal2, Francisco Roldán2, Rodrigo Fasce1, Eugenio Ramírez2.   

Abstract

Diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) cases is based on the count of real-time reverse transcription-plymerase chain reaction (RT-PCR) positive people. Viral load by real-time RT-PCR has been suggested as a biomarker of the SARS-CoV-2 infection. However, the association of viral load and severity of the disease is not yet resolved. Nasopharyngeal samples from 458 patients were tested by RT-PCR for SARS-CoV-2 diagnosis. Relative quantitation was made by the comparative threshold cycle (ΔΔCt ) formula between ORF1ab viral and RNase P housekeeping genes. Absolute viral load was calculate using a reference positive control. Most prevalent clinical signs were cough (75.8%), myalgia (66.7%), and fever (48.5%). Hypertension (18.2%), neurological diseases (15.1%), and asthma and hypothyroidism (12.1%) were most frequent comorbidities. Fever, either as an exclusive symptom or combined with others, was associated with high viral loads ( 2 - ∆ ∆ C t range, 35.65-155.16; 4.25-4.89 log10 RNA copies/test]). During the first week after onset of symptoms in mild patients up to 60 years-old was detected the peak of viral load. Children under 10 years old have a high viral load (313.84; 2.50) in the first 2 days postinfection with a sharp decline thereafter. Cases between 10 and 49 years old mostly showed low and moderate viral load during the first 2 days postinfection (range, 0.03 to 17.24; -1.50 to 1.24). Patients over 60 years old have high viral load up to the second week after the onset of symptoms (range, 25.32-155.42; 1.40-2.19), indicating the longer presence of the virus in them. These findings suggest the viral load in nasopharyngeal swabs would help to monitor the SARS-CoV-2 infection in mild coronavirus disease 2019 cases.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  SARS-CoV-2; nasopharyngeal samples; quantitative detection of SARS-CoV-2 RNA

Year:  2021        PMID: 33368332     DOI: 10.1002/jmv.26761

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

1.  A first probable case of SARS-CoV-2 reinfection in Colombia.

Authors:  Whilken Novoa; Hollman Miller; Salim Mattar; Álvaro A Faccini-Martínez; Ricardo Rivero; Hector Serrano-Coll
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-01-12       Impact factor: 3.944

2.  Longitudinal Systemic and Mucosal Immune Responses to SARS-CoV-2 Infection.

Authors:  Peter F Wright; Alejandra C Prevost-Reilly; Harini Natarajan; Elizabeth B Brickley; Ruth I Connor; Wendy F Wieland-Alter; Anna S Miele; Joshua A Weiner; Robert D Nerenz; Margaret E Ackerman
Journal:  J Infect Dis       Date:  2022-09-28       Impact factor: 7.759

3.  Correlation of SARS-CoV-2 Viral Load and Clinical Evolution of Pediatric Patients in a General Hospital From Buenos Aires, Argentina.

Authors:  Martín Eduardo Brizuela; Sandra Elizabeth Goñi; Georgina Alexandra Cardama; María Alejandra Zinni; Alejandro Andres Castello; Leandro Matías Sommese; Hernán Gabriel Farina
Journal:  Front Pediatr       Date:  2022-07-07       Impact factor: 3.569

4.  Lower nasopharyngeal viral loads in pediatric population. The missing piece to understand SARS-CoV-2 infection in children?

Authors:  Emilio Cendejas-Bueno; María P Romero-Gómez; Luis Escosa; Sonia Jiménez-Rodríguez; Jesús Mingorance; Julio García-Rodríguez
Journal:  J Infect       Date:  2021-06-13       Impact factor: 6.072

5.  Open-source real-time quantitative RT-PCR-based on a RNA standard for the assessment of SARS-CoV-2 viral load.

Authors:  Juliana Comerlato; Carolina Baldisserotto Comerlato; Fernando Hayashi Sant'Anna; Marina Bessel; Celina Monteiro Abreu; Eliana Márcia Wendland
Journal:  Mem Inst Oswaldo Cruz       Date:  2022-01-28       Impact factor: 2.743

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.